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Abstract Uveal melanoma (UM), a rare cancer of the
eye, is distinct from cutaneous melanoma by its etiolo-
gy, the mutation frequency and profile, and its clinical
behavior including resistance to targeted therapy and
immune checkpoint blockers. Primary disease is effi-
ciently controlled by surgery or radiation therapy, but
about half of UMs develop distant metastasis mostly
to the liver. Survival of patients with metastasis is be-
low 1 year and has not improved in decades. Recent
years have brought a deep understanding of UM biolo-
gy characterized by initiating mutations in the G pro-
teins GNAQ and GNA11. Cytogenetic alterations, in
particular monosomy of chromosome 3 and amplifica-
tion of the long arm of chromosome 8, and mutation
of the BRCA1-associated protein 1, BAP1, a tumor sup-
pressor gene, or the splicing factor SF3B1 determine
UM metastasis. Cytogenetic and molecular profiling al-
low for a very precise prognostication that is still not
matched by efficacious adjuvant therapies. G protein
signaling has been shown to activate the YAP/TAZ
pathway independent of HIPPO, and conventional sig-
naling via the mitogen-activated kinase pathway proba-
b ly a lso cont r ibu tes to UM development and
progression. Several lines of evidence indicate that in-
flammation and macrophages play a pro-tumor role in
UM and in its hepatic metastases. UM cells benefit
from the immune privilege in the eye and may adopt
several mechanisms involved in this privilege for tumor
escape that act even after leaving the niche. Here, we
review the current knowledge of the biology of UM and
discuss recent approaches to UM treatment.
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1 Introduction
Uveal melanoma (UM) is a rare disease but the most frequent
non-cutaneous melanoma and the most frequent primary can-
cer of the eye in the adult. In recent years, our understanding
of this disease has made a leap forward through the identifi-
cation of the molecular players likely responsible for tumor
initiation and progression. The process of multistep carcino-
genesis is now known in considerable detail, perhaps better
than for any other neoplasia, and prognosis can be made with
utmost precision. This is contrasted by the lack of adjuvant
therapy and low efficacy of therapy for metastatic UM, lead-
ing to survival rates that have not significantly changed over
decades.
This review gives a general overview of the current knowl-
edge in the field of UM, incorporating the most relevant find-
ings on the biology of this disease and their implications in
clinical management. Reference to recent reviews that give
more detailed descriptions is given wherever possible.
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2 Clinical features of uveal melanoma
2.1 Epidemiology
Approximately 5% of all melanomas affect the eye, making it the
most common site for melanoma development after the skin [1].
The vast majority (85%) of ocular melanomas occur in the uveal
tract, which is the vascular layer of the eye (comprising the
choroid, the ciliary body, and the iris), and hence are known as
UM. Conjunctival melanoma is a rare tumor that develops in the
mucous membrane lining the inner surface of the eyelids and the
forepart of the eyeball. The clinical and histopathological features
of conjunctival and uveal melanomas are clearly different; hence,
the two entities should not be confused. Uveal melanoma has
molecular affinities with melanocytic tumors of the central ner-
vous system [2]whereas conjunctival melanomas showmutation
patterns similar to cutaneous melanoma (CM) [3, 4].
The incidence of UM in the USA is 4.3 per million (4.1–
4.5; 95% confidence interval [CI]) with a prevalence in males
(males, 4.9 [4.6–5.2], 95% CI; females, 3.7 [3.5–3.9], 95%
CI). Of the cases registered, 97.8% occurred in the white pop-
ulation [5]. There is a strong difference in the incidence for
different ethnic groups: the annual age-adjusted incidence is
0.31 for Afro-Americans, 0.38 for Asians, 1.67 for Hispanics,
and 6.02 for non-Hispanic whites [6], yet prognosis does not
differ for ethnic groups [7]. The European Cancer Registry-
based study on survival and care of cancer patients
(EUROCARE) for the years 1983–1994 reported similar in-
cidence rates with a characteristic increase from south to
north, from <2 per million in Spain and Southern Italy to >8
per million in Norway and Denmark [8]. This is consistent
with increasing incidence observed with increasing latitude
in the USA (4.91-fold from 20–22° to 47–48°) [9].
UM has been reported in patients of all ages, but only 1% of
cases occur in younger patients under the age of 18. The inci-
dence increases with age, peaking at the age of 70. The age-
adjusted incidence rate was stable between 1973 and 1997 in the
USA [5].More recently, an increase in themean age at diagnosis
for the interval between 1973 and 2009 was described based on
the analysis of 7043 UM patients from the Surveillance,
Epidemiology, and End Results Program (SEER) database
[10]. This increase is most likely attributable to the growing
life-span and more thorough screening for eye diseases.
Five-year relative survival of UM patients was 68.9% [11],
81.6% [12], and 81.4% [13] for cases diagnosed in Europe
(1983–1994), the USA (1973–2008), and Western Australia
(1981–2005), respectively. Death rates were slightly elevated
in older patients and in males. The general trend in prolonged
survival after cancer diagnosis [14, 15] does not apply to UM:
no significant differences in overall survival or disease-specific
survival were observed between 1973 and 2009 when the data
were stratified by year of diagnosis [10–12]. UM thus belongs
to the few cancers with stable or increasing death rates.
2.2 Etiology
The etiology of UM is still unclear. UV radiation has clearly
been identified as the major risk factor for CM [16], but the
role of UV radiation in the development of UM is still under
debate [17]. Cornea, lens, and vitreous body absorb almost all
wavelengths below 300 nm and much of the spectrum be-
tween 300 and 400 nm [18]. However, age-dependent alter-
ations of the vitreous body [19] might alter the absorptive
capacity of the latter. The associations between UM risk and
blue iris or a generally weakly pigmented phenotype [20, 21]
and sun exposure [22] suggest a role for UV radiation in the
etiology of UM. A meta-analysis of 133 reports on UV-
associated risk factors for UM showed a significant correla-
tion for welding (OR = 2.05; CI 1.20–3.51) but not for outdoor
leisure activities (OR = 0.86; CI 0.71–1.04), occupational
sunlight exposure (OR = 1.37; CI 0.96–1.96), and latitude of
birth (OR = 1.08, CI 0.67–1.74) [23]. If there is a role for UV
light in UM etiology, it is certainly by far weaker than that for
CM. The etiologic effect of UV radiation for UM is likely too
weak to overcome confounding factors such as co-distribution
of weakly pigmented skin and iris and latitude, co-occurrence
of UV radiation with light of longer wavelengths, and protec-
tive, vitamin D-mediated effects of sun exposure [24]. Violet/
blue light, the most energetic form next to UV light, has also
been cited as a potential risk factor for UM [25]. Genetic
variants on chromosome 15q13.1, close to the genes
HERC2 and OCA2 on 15q12 that are involved in the deter-
mination of eye color, have been found associated with UM
risk [26], and the G proteins GNAQ and GNA11 that are
frequently mutated in UM [27, 28] are involved in the deter-
mination of skin color in mice [29].
In contrast to inconclusive epidemiological data, mo-
lecular data can clearly exclude a typical UV-associated
mutational spectrum for UM; in fact, it shows a relatively
low mutational load when analyzed by whole exome se-
quencing and no enrichment for UV-typical C>T transi-
tions at dipyrimidine sites [27, 28, 30–32]. UV-induced
mutations in the promoter of the human Telomerase
Reverse Transcriptase (TERT) gene occur in approximate-
ly 70% of CMs [33, 34] but are rare in UMs [35–37].
Hence, if light has a role in UM carcinogenesis, it certain-
ly acts in a different manner than in CM.
2.3 Diagnosis and treatment
UM can develop without any symptom and is diagnosed by
routine ophthalmic examination [38]. It often causes painless
distortion of vision and other non-specific visual symptoms
[39]. Diagnosis of UM relies primarily on clinical examination
and ocular ultrasonography [40]. On the hand of an experienced
ocular oncologist, elevated levels of accuracy [41] and first visit
detection rates [38, 39] have been documented, minimizing the
110 Cancer Metastasis Rev (2017) 36:109–140
need for invasive diagnostic biopsy [42]. There might be an
effect of the time of intervention especially for smaller tumors,
and diagnostic delay in older patientsmight affect prognosis [43].
Treatment options include local radiotherapy (106ruthenium or
125iodine brachytherapy, proton beam therapy, or stereotactic ra-
diosurgery) or surgery (local resection, endoresection, or enucle-
ation) [42]. Neoadjuvant phototherapy has been proposed with
the scope of reducing side effects of brachytherapy [44].
Local control of disease reaches 96.4% after proton beam
therapy [45, 46], but local recurrence can arise up to almost
10 years after primary therapy and determines an increased
metastatic risk [47, 48].
2.4 Metastatic disease
Despite successful local treatment, 25 and 34% of UM
patients develop metastases within 5 and 10 years, respec-
tively [49]. The long-term cumulative melanoma-related
mortality rate 25 years after primary treatment is over
50% for medium and large tumors [50]. High-risk cases
(see below) should be integrated in a lifelong surveillance
program including liver imaging for early detection of
metastases [42] since it is the first site of metastasis of
UM in most cases [49, 51, 52]. Based on self-reported
outcome measures, quality of life reaches levels of the
healthy population 6 months after treatment with some
stress for younger and female patients and depression in
patients with bad prognosis [53].
At present, there is no approved adjuvant therapy for UM, a
fact that is in striking contrast with the elevated precision in
prognostication (see below). Interferon-α2a (IFN-α2a [45] and
methanol-extracted residue of Bacillus Calmette–Guerin [46]
have been tested as an adjuvant therapy but did not affect sur-
vival. A trial with 22 patients to test adjuvant intra-arterial hepatic
Fotemustine showed effects on survival together with consider-
able toxicity but did not reach statistical significance [47].
Several adjuvant trials are registered at the clinical trials service
of the National Institute of Health (clinicaltrials.gov). The anti-
vascular endothelial growth factor (VEGF) drugAvastin is being
tested in a neoadjuvant setting for its capacity to reduce larger
UM prior to therapy (NCT005963621). Dendritic cells and vac-
cine therapies are being tested (NCT00929019, NCT01983748,
NCT00020475) aswell as the anti-receptor tyrosine kinase drugs
crizotinib (NCT02223819) and sunitinib alone (NCT02068586)
or in combinationwith tamoxifen and cisplatin (NCT00489944),
and the histone deacetylase inhibitor valproic acid
(NCT02068586). Adjuvant chemotherapy is presently investi-
gated in two trials (dacarbazine in combinationwith recombinant
IFN-α2b [NCT01100528] and fotemustine [NCT02843386]) as
well as prophylactic hepatic irradiation (NCT02336763). All
these trials rely on advanced prognostic testing (see below).
UM is also contemplated in several trials for CM.
The mean survival after diagnosis of metastatic UM is ap-
proximately 1 year [54, 55], but a considerable proportion of
patients survive more than 4 years [51]. Resection of liver
metastases can be performed in relatively few patients where
it shows some advantage in survival [56–59] and appears to
work better for UM than for CM [60]. Hepatic intra-arterial
chemotherapy improves progression-free survival but not
overall survival [61]. A phase II trial reveals a 14-month gain
in survival [62], indicating that isolated hepatic perfusion is
active on established liver metastases [63, 64]. A phase III trial
is presently recruiting [62].
At present, ClinicalTrials.gov lists 69 trials for metastatic
UM (for recent reviews, see [65, 66]). Targeted therapies
based on the activation of the mitogen-activated protein
(MAP) kinase pathway by mutated G protein GNAQ or
GNA11 have been tested in several clinical trials. Selumetinib
that inhibits the MAP kinase kinase enzymes MEK1 and
MEK2 showed a slight improvement in progression-free sur-
vival [67] that, according to a preliminary report, was not con-
firmed in a phase III trial [68, 69]. Selumetinib is also being
tested in combination with temozolomide (NCT01143402),
and the maximum tolerated dose of intermittent selumetinib is
being investigated (NCT02768766) [69]. Bevacizumab was
tested in combination with dacarbazine showing modest activ-
ity [70]. A pilot study with the kinase inhibitor sunitinib
showed a potential clinical benefit that was independent of
the expression level of the target kinase, c-Kit [71]. An institu-
tional review from Mayo Clinic showed that local therapies
were superior to kinase inhibitors [72].
For now, MAP kinase-targeted therapies for UM cannot
equal the successes obtained for CM. Similarly, immune
checkpoint blockade therapy using antibodies directed against
immunomodulatory receptors and ligands induces long-term
survival in a considerable portion of CM patients [73] but
shows only limited activity in metastatic UM patients with
extended responses in some patients [74–83]. A recent phase
I trial with AM0010, a pegylated recombinant IL-10, showed
responses of solid tumors with BRCA1-associated protein 1
(BAP1) mutations, among which is a UM [84].
Many preclinical studies have addressed UM therapy by
analyzing the expression and function of pathways that are
target for existing drugs [85–118]. These studies have not
led to clinical trials, or the trials did not confirm the activity
of the drug in UM patients, as for example for c-Kit-targeted
treatment with Gleevec [87].
Table 1 summarizes these efforts.
The ADP ribosylation factor 6 (ARF6), not to be mistaken
for the tumor suppressor gene (TSG) p16/INK4a-ARF, has
recently been identified as a major hub for oncogenic signal-
ing in UM [91]. ARF6 responds to the activation of several
pathways that have been targeted in preclinical studies, among
1 ClinicalTrials.gov identifiers are indicated in parentheses for clinical trials
throughout the text.
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which are the epidermal growth factor receptor (EGFR) [119],
the VEGF receptor [120], and the wingless-type MMTV inte-
gration site family of signaling protein (WNT) [121] path-
ways. In mice, ARF GTPase-activating proteins control c-kit
endocytosis [122].
2.5 Histopathology
The diagnosis of UM is generally made by a trained ophthal-
mologic oncologist, and only few cases require cellular anal-
yses in order to rule out an ocular metastasis of other solid
tumors. Histopathology is primarily required for prognostica-
tion of UM [123]. Nuclear grade and cell type are linked to
prognosis. Tumors dominated by epithelioid cells have a
worse prognosis than those with prevalently spindle-like cells.
Tumors with a mixed cell type have an intermediate risk
[123–125]. The proportion of spindle cell histology is more
frequent in younger patients and has decreased over time [10],
probably as a consequence of increased age at diagnosis.
Accordingly, metastatic UM shows prevalently epithelioid
cells although a component of spindle-like cells is always
present [126]. Other histopathological features commonly
used for assessing the malignant potential of UM are the num-
ber of mitotic figures and the presence of extracellular matrix
periodic acid–Schiff-positive closed loops.
More recently, immunohistochemistry has been proposed
as a useful prognostic tool for the analysis of nuclear expres-
sion of the BAP1. The somatic mutation of this gene, resulting
in a loss of protein expression, is associated with metastatic
risk [127–130] (see below).
3 Genetics of uveal melanoma
3.1 Cytogenetics
The most frequent cytogenetic alterations encountered in UM
are monosomy of chromosome 3 and amplification of 8q [131,
132], both associated with poor prognosis [133, 134]. The am-
plifications are conserved in metastases [135]. Amplification of
chromosome 6p [132, 136] and losses of 1p are also frequent
[137]. Table 2 summarizes the results of studies analyzing large
cohorts by microsatellite analysis [140, 141], fluorescence in
situ hybridization (FISH) [142, 143], multiplex ligand-
dependent PCR amplification (MLPA) [139], or single nucleo-
tide polymorphism (SNP) microarrays [143]. These studies
confirm the strong association of monosomy of chromosome
3 with death from metastasis as well as with other histopatho-
logical factors such as epithelioid cells, closed microvascular
loops, ciliary body involvement, large basal tumor diameter,
and tumor thickness. The latter two remain to be important
histopathological prognostic factors [144, 145]. Also the highly
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occur independent of each other, and principal component anal-
ysis of karyotypes identifies four classes with prognostic rele-
vance: (i) disomy 3/disomic 8q, (ii) monosomy 3/disomic 8q,
(iii) disomy 3/8q gain, and (iv) monosomy 3/8q gain [146].
Three to seven copies of 8q could be detected [138]. Digital
PCR which offers the possibility to detect rare events in het-
erogeneous tissue samples might further improve the prognos-
tic power of molecular cytogenetics [147]. All chromosomal
alterations except amplification of 6p correlate with the largest
basal tumor diameter, indicating that they do not occur at the
onset of the disease but they are acquired later on [43].
It is clear that monosomy of chromosome 3 is the single
strongest cytogenetic factor to predict UM metastasis. Almost
all cancers show chromosomal aberrations. Often, tumors con-
tain a mutated, non-functional allele of a TSG and the function-
al wild-type allele is lost by deletion. This has also been shown
for UM where the tumor suppressor gene BAP1, located on
3p21.1, frequently shows somatic mutations in the only allele
present in tumors with monosomy of chromosome 3 [148].
However, in contrast to other tumors, a loss of BAP1 function
appears not to be sufficient. Most metastatic tumors show com-
plete monosomy, but there are many cases with partial mono-
somy, indicating that it is not the result of mitotic non-
disjunction of the entire chromosome. Interestingly, smaller
tumors with a lower metastatic risk show a higher proportion
of cases with partial monosomy 3 [140]. Hence, there must be a
selective advantage for the loss of an entire chromosome 3.
Principal component analysis of the results of an MLPA-
based screening of chromosome 3 confirmed the association
of metastasis risk with the loss of the entire chromosome rather
than a single region therefrom [146]. The identification of the
smallest overlapping regions (LOR) usually leads to the iden-
tification of TSGs. However, this approach has not worked out
for UM where two LORs were identified but none of them
contained BAP1 [149] that was later identified by exome se-
quencing. A similar, microsatellite-based analysis identified an
adjacent lesion in 3p25.1–3p25.2 that also does not contain
BAP1 [150]. Several cases with deletions spanning the BAP1
locus were identified in a bacterial artificial chromosome-based
comparative genome hybridization study, yet the gene was not
identified [151]. Isodisomy of chromosome 3 also occurs [152]
and is apparently associated with a metastatic risk of UM [153].
The nature of the apparent selective advantage of monosomy or
isodisomy over the simple deletion of the wild-type copy of
BAP1 and the reason why BAP1 did not consistently show up
in the cytogenetics-based tumor suppressor gene research is
unknown. The p53 apoptosis effector (PERP) is expressed at
low levels in UM with monosomy 3 [154], and the tumor
protein p63, encoded by the TP63 gene, located on chromo-
some 3q27–29, has been shown to be necessary to promote
apoptosis in tumor protein p53 (TP53) wild-type UM cell lines.
Yet, the role of monosomy remains unclear since the study used
disomic cell lines and did not analyze UM tumors [155].
Copy number alteration analysis using SNP arrays has re-
vealed several amplifications and deletions, among which are
amplifications on chromosome 6q25.2 containing the
membrane-associated guanylate kinase interacting protein-
like 1 (CNKSR3) that was amplified in a specific rare subset
of UM with monosomy of chromosome 3 and extended
metastasis-free survival [156].
3.2 Somatic mutations
Whole exome sequencing [30, 32, 157], including The Cancer
Genome Atlas (TCGA) data (http://cancergenome.nih.gov/),
shows that UM has relatively few recurring mutations,
indicating a low genetic complexity and the absence of
genomic instability. Many studies report mutation
frequencies that are summarized in Table 3 [27, 28, 30, 32,
35, 83, 126, 128, 130, 147, 148, 157–172]. Initially, BRAF
mutations had also been described for UM [173, 174] but
these reports have not been confirmed.
Table 2 Chromosomal deletions and amplifications in uveal melanoma (%)
No. of
cases
Sample type Method Chromosome Reference
3 1p 6p 6q 8q 8p
Monosomy Partial
monosomy
Losses Gains Losses Gains Gains Losses Gains
356 Local resection or enucleation FISH 47 37 [138]
452 Local resection or enucleation MLPA 61 54 22 63 18 [139]
500 Fine needle aspiration biopsy MS 25 27 [140]
374 Enucleation MS 56 54 [141]
220 Enucleation FISH 61 42 30 61 [142]
320 Fine needle aspiration biopsy
or enucleation
SNVarrays 45 6 18 32 17 6 51 18 16 [143]
Total 54 42 22 53
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GNAQ [27] and GNA11 [28], two genes encoding Gα
subunits of G proteins, are considered the major drivers of
UM carcinogenesis since they are found in a mutually exclu-
sive manner in over 80% of UM (see Table 3) where they
occur in most if not all of the cells forming the tumor [158].
A significantly lower frequency has been reported for patients
from China [170]. Mutations in GNA11 but not GNAQ have
been found more frequently in metastatic UM [28, 126]. All
mutations of GNAQ and GNA11 in UM involve the same two
hotspots in both genes, Q209 and, less frequently, R183, in the
Ras-like GTPase domain [175]. These mutations are also en-
countered in blue nevi and nevi of Ota [176] and melanocytic
tumors of the central nervous system [177]. The somatic mo-
saic GNAQ R183Q mutation is associated with the
neurocutaneous disorder Sturge–Weber syndrome and non-
syndromic port wine stains [178]. The exclusively somatic
nature of the mutation in the Sturge–Weber syndrome and
the absence of GNAQ and GNA11 germline mutations in
familiar cases of UM [179] suggest that the germline muta-
tion, if present in all cells, is not compatible with life.
Consistent with their oncogenic function, GNAQ and
GNA11 mutations in UM are activating mutations. GNAQ
and GNA11 are activated by the serotonin (5-HT) receptors
2A and 2B (HTR2A and HTR2B) [180]. The role of serotonin
in uveal melanocytes is unknown, but the involvement of the
neurotransmitter in the regulation of proliferation, cell shape,
and migration of melanocytes has been described for frog skin
[181]. Interestingly, HTR2B, the gene encoding the serotonin
receptor 5-HT2B, is overexpressed in UM with high metasta-
tic risk [182, 183] despite the fact that the activating mutations
Table 3 Frequent somatic mutations in primary uveal melanoma
No. of
samples
Potential driver mutations Metastasis drivers Reference
GNAQ GNA11 CYSLTR2 PLCB4 BAP1 SF3B1 EIF1AX
67 49% (33/67) [158]
48 46% (22/48) [27]
75 53% (40/75) [159]
22 36% (8/22) [2]
27 44% (12/27) [2]
163 48% (55/115) 34% (55/163) [28]
57 47% (7/15) 47% (27/57) [148]
91 47% (43/91) 44% (40/91) [160]
102 42% (36/86) 52% (43/83) 38% (32/85) 19% (19/102) [32]
117 25% (3/12) 58% (7/12) 58% (7/12) 15% (18/117) 8% (1/12) [161]
111a 41% (9/22) 41% (9/22) 11% (5/45) 20% (20/111) 21% (23/111) [30]
92 35% (6/17) 43% (40/92) [162]
74 47% (35/74) [128]
50 18% (9/50) 20% (10/50) [156]
46 42% (19/45) 33% (15/46) 32% (12/38) 10% (3/31) 19% (7/37) [35]
116 46% (52/113) 35% (41/116) 50% (56/111) 10% (11/110) 16% (18/111) [163]
66 41% (27/66) 50% (33/66) [147]
123 48% (59/123) 46% (57/123) [164]
23 35% (8/23) 39% (9/23) 9% (2/23) 35% (8/23) 9% (2/23) 17% (4/23) [157]
74 22% (16/74) [165]
7 29% (2/7) 57% (4/7) 57% (4/7) [130]
81 44% (36/81) 44% (36/81) 45% (29/64) 23% (19/81) 17% (14/81) [166]
158 52% (67/130) 44% (57/130) 51% (81/158) 22% (29/131) 17% (23/133) [167]
133 49% (67/132) 38% (44/117) 75% (9/12) 24% (32/133) 21% (28/133) [168]
15a 53% (8/15) 40% (6/15) [83]
136 43% (58/136) 49% (67/136) 3% (4/136) 4% (5/136) 35% (48/136) 18% (24/136) 13% (18/136) [169]
65 43% (28/65) [130]
2013 45% (686/1518) 42% (573/1373) 3% (4/136) 4% (7/159) 43% (381/887) 18% (193/1049) 18% (136/777)
Range (%)b 18–53 20–58 3 4–9 32–75 9–24 8–21
a Selected patients
b Studies with selected patients not considered
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in GNAQ and GNA11 already activate the pathway. The
endothelin receptor types A and B (EDNRA and EDNRB)
also signal via GNAQ and GNA11 [184, 185]. Endothelin 2
is differentially expressed in UM [186], and its receptor
EDNRB is downregulated in metastatic UM [187]. Evidence
frommice indicates that endothelin signaling could be specific
for Schwann cell precursor-derivedmelanocytes that also pop-
ulate the uvea [188].
GNAQ and GNA11 activate the classical G protein signal-
ing cascade via inositol-3-phosphate, diacylglycerol, and cy-
clic AMP, leading to the stimulation of MAP kinases, protein
kinase B (Akt) and protein kinase C (PKC), phosphoinositide
3-kinase (PI3K), and mechanistic target of rapamycin
(mTOR) [189]. More recently, GNAQ and GNA11 have been
shown to activate the transcription factor complex YAP/TAZ
in a HIPPO-independent manner [93, 190]. HIPPO has been
identified as an important regulator of organ size, and its in-
volvement in several cancer types has recently been appreci-
ated [191]. At present, it is not clear which of the two path-
ways, YAP/TAZ or MAP kinase, is more important in UM.
Interestingly, activation of YAP/TAZ has been shown to con-
fer resistance to BRAF-targeted therapy in CM [192]. MAPK-
targeted therapy has so far not been successful in UM (see
above), and YAP/TAZ inhibitionmight become an alternative.
The YAP/TAZ pathway can be interrupted by the photody-
namic drug verteporfin [93] and through inhibition of the
mevalonate pathway [193]. The stimulation of several signal-
ing pathways including activation and nuclear translocation of
β-catenin by mutated GNAQ and GNA11 proteins relies on
the small GTPase ARF6 [91]. Its inhibition by the small mol-
ecule inhibitor NAV-2729 leads to the reduced growth of
GNAQ mutant cells in vitro and in vivo [91].
Fifteen to twenty percent of UM show no mutations in
GNAQ and GNA11 genes. The analysis of whole exome se-
quencing data in double wild-type UM has led to the identifica-
tion of a L129G-activating mutation in the cysteinyl leukotriene
receptor 2 (CYSLTR2) gene, coding for a G protein-coupled
receptor. The mutation leads to constitutive activation of
GNAQ signaling [169]. The D630Y mutation in the phospholi-
pase Cβ4 (PLCB4) gene that has been observed in several
GNAQ and GNA11 wild-type UM cases activates the same
pathway acting downstream of GNAQ by catalyzing the forma-
tion of inositol 1,4,5-trisphosphate and diacylglycerol from
phosphatidylinositol 4,5-bisphosphate [157]. In only a minor
part of UM, no putative oncogenic mutation has been found
so far. Mutations in the genes GNAQ, GNA11, CYSLTR2,
and PCLB4 are likely the initiating driver mutations of UM.
The BAP1 gene encodes a nuclear ubiquitin carboxy-
terminal hydrolase with deubiquitinase activity [194] that be-
haves like a classical TSG in UM [148]. It is located on chro-
mosome 3p21.1, and 84% of metastatic UMmaintain only the
mutated allele of BAP1 [148]. Germline mutations in BAP1
are associated with several familiar cancers, among which are
lung adenocarcinoma, meningioma, mesothelioma, CM, and
UM [195–200]. The specific type of cancer that develops in
BAP1 mutation carriers might depend on additional modifier
genes [201]. Eight percent of patients with metastatic UM
carried germline BAP1 mutations [198], and the penetrance
in consideration of all types of malignancy approaches 70%
and might increase with increasing age of the unaffected
BAP1 carriers [200]. Germline BAP1 mutations could be
more frequent in patients with early onset of UM [202].
Similar to what has been observed for other TSGs, loss of
function mutations can occur over the whole coding region
of the gene and mutation is associated with a loss of protein
expression. For prognostication, immunohistochemistry has
been established as a reliable method to predict BAP1 muta-
tion [127–130].
BAP1 is associated with BRCA1 but does not lead to its
deubiquitylation. Instead, it deubiquitylates BRCA1-
associated RING domain 1 (BARD1) and modulates the E3
ligase activity of the complex formed by BRCA1 and BARD1
that is needed for the regulation of the DNA damage response
[203]. The tumor suppressor activity of BAP1 requires
deubiquitylation activity and nuclear localization [204].
Among the substrates of BAP1, there is the repressive tran-
scriptional regulator host cell factor 1 (HCF1) that acts on
E2F-responsive promoters [205]. BAP1 also controls tran-
scription and chromatin structure via histone H2A
deubiquitylation [206] and through its interaction with
HCF1 and the transcription factor Yin Yang 1 (YY1) affecting
the transcription of many genes [207, 208]. Consistent with
the profound effect on the transcription profile of the cells,
depletion of BAP1 determines cell dedifferentiation and the
acquisition of stem cell features [209]. The effect on H2A can
be controlled by histone deacetylase inhibitors [115] that are
present ly tested in the cl inics as a single agent
(NCT00121225, NCT01587352) or in combination with im-
mune checkpoint blockers (NCT02697630).
The Splicing Factor 3b Subunit 1 gene (SF3B1) is mutated
in positions R625 [32, 161] and K666 [165] in a minority of
UM cases, almost always in the absence of BAP1 mutations.
These mutations only rarely occur in CM [210, 211]. SF3B1 is
frequently mutated in hematopoietic malignancies with, how-
ever, another mutation hotspot in K700 [165] with likely the
same or similar functional consequences. SF3B1 mutation
alters its function in RNA splicing, leading to the selection
of cryptic splice sites [165, 212, 213] thus affecting many
primary transcripts. It is therefore not possible to classify
SF3B1 mutations in activating or inactivating mutations.
SF3B1 mutations define a subclass of UM with chromosome
3 disomy and without BAP1 mutations that nevertheless de-
velop metastases after extended latency [167, 214, 215]. This
subclass is distinguished by overexpression of the preferen-
tially expressed antigen in melanoma (PRAME) [215] which
acts as a dominant repressor of retinoic acid receptor signaling
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[216], and its expression is controlled by promoter methyla-
tion and is associated with a metastatic risk in SF3B1 as well
as in BAP1 mutated cases [217].
Missense mutations in the highly conserved amino-
terminal portion of the Eukaryotic Translation Initiation
Factor 1A X-Linked (EIF1AX) gene also occur prevalently
in the absence of BAP1 mutations in disomic, low-risk UM
[30]. The association of EIF1AX mutations with a low-risk
profile has been confirmed in an independent study [163].
EIF1AX stimulates the transfer of methionyl initiator tRNA
(Met-tRNAi) to the small ribosomal subunit during translation
initiation. The functional consequences of these mutations are
unknown, and the involvement of alternative start codon rec-
ognition has been suggested [30]. BAP1, SF3B1, and
EIF1AX mutations are almost mutually exclusive and associ-
ated with early (BAP1), late (SF3B1), or no (EIF1AX) metas-
tasis (see Fig. 1). EIF1AX mutations are present in 18% of
UM (Table 3), likely due to positive selection during carcino-
genesis. UMwith mutations in this gene have, however, a low
risk of metastasis. Hence, EIF1AX is pro-tumorigenic with no
or negative influence on metastasis or the link between its
mutations and a specific pattern of metastasis is still unknown.
The Catalogue of Somatic Mutations in Cancer (COSMIC,
http://cancer.sanger.ac.uk/cosmic) reports 58 mutations of
Fig. 1 Gene expression and mutational status in UM. Gene expression
data from 79 cases of primary UM from the TCGA cohort were used for
the identification of genes that are differentially expressed in cases that
yielded distant metastases later on as compared to cases without
progression to metastatic disease. Statistically significant gene
expression differences were obtained by analysis using the
bootstrapping algorithm significance analysis of microarrays as
described [84]. Expression values over the mean value are indicated in
red, values below the mean in blue, and values at the mean in white; the
intensity of the color corresponds to the distances from the mean as
indicated in the red-blue bar on top of the diagram. Differentially
expressed genes were used for hierarchical clustering performed as
described [84]. The dendrograms on top of the gene expression panel
show the relationship of single samples and their agglomeration in
clusters. The differences between the clusters are indicated by the
length of the branches of the dendrograms. Above the dendrogram, the
mutational status for GNAQ, GNA11, BAP1, SF3B1, and EIF1AX is
indicated as well as chromosomal alterations (chromosome 3
monosomy, 6p and 8q gains) and the development of distant metastases
and the status of the patients at the end of the follow-up. In all these cases,
colored boxes indicate the presence and white boxes the absence of the
alteration. Two main clusters are formed, one of which contains most of
the cases that developed metastases. The mutation status of these cases
evidences the correlation between chromosome 3 monosomy, BAP1
mutation, metastasis, and death. Note that this cohort contains an
unusual case with mutations in both GNAQ and GNA11
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EIF1AX in 33,058 cancers analyzed and occasional copy
number changes, gains, and losses. EIF1AX mutations also
occur in papillary [218] and anaplastic [219] thyroid
carcinoma and serous ovarian tumors [220]. EIF1AX
mutations are missense mutations mainly clustered in the
amino-terminal portion of the encoded protein with some
frameshift deletions in UM and a splice site mutation hotspot
in thyroid cancer [220].
Figure 1 shows a combined view of frequent somatic mu-
tations in UM and their associations with clinical features and
gene expression in the TCGA dataset of 79 UM cases.
3.3 Gene expression
Several groups have assembled significant numbers of expres-
sion profiles of UM samples [182, 183, 221–223] which, in
part, are publicly available. The TCGA dataset also contains
gene expression profiles (GEPs) obtained by RNA sequencing.
From the very first analysis, it was evident that the major hall-
mark of high-risk UM, chromosome 3 monosomy, is clearly
associated with a specific expression profile [182]. This has
been confirmed and extended by several other studies [153,
183, 224, 225] and has led to the development of a multigene
prognostic classifier [225–229] (see also Fig. 1) with a prog-
nostic power at least similar to cytogenetics-based procedures
such as MLPA [139], eventually combined with histopatholog-
ical criteria [144]. Public UM gene expression datasets build a
domain knowledge that can be mined for many studies such as
the expression analysis of targets for existing drugs [85, 222].
The gene expression-based classification of UM shows two
very robust classes (Fig. 1) similar to what has been observed for
breast cancer where the expression of the estrogen receptor α
(ESR1) gene defines two classeswith clearly distinguishedGEPs
[230]. The differences between these classes have been proposed
to be determined by their origin, from either luminal or basal cells
[231]. Cell lineage is in fact a major determinant of GEPs [232].
When applied to UM, this could indicate that tumors with mono-
somy 3 are derived from different precursor cells than disomic
cases with a different intrinsic propensity to metastasize.
Several studies have performed microRNA (miRNA) expres-
sion screenings in UM (for a recent review, see [233]). miRNA
expression is associated with chromosome 3 status, gene expres-
sion profiling classes and prognosis [234]. Functional studies
have been performed for selected miRNAs identified in cell lines
or very limited sample collections of UM [233]. There is no
conclusive evidence for a functional role of miRNA dysregula-
tion in UM due to the lack of large-scale analyses.
4 Multistep carcinogenesis
Our current understanding of how cancer develops is based on
three concepts that, to some extent, present a conceptual
evolution: (i) the two hits hypothesis postulating that transfor-
mation of a normal cell into a cancer cell needs at least two
irreversible steps [235, 236], usually mutations in oncogenes
and tumor suppressor genes; (ii) the multistep carcinogenesis
model that predicts distinct morphological changes during tu-
mor development based on specific molecular lesions [237];
and (iii) the hallmarks of cancer concept that establish distinct
processes during cancer evolution: sustaining proliferative
signaling, evading growth suppressors, avoiding immune de-
struction, enabling replicative immortality, genome instability
and mutation, resisting cell death, deregulating cellular ener-
getics, tumor-promoting inflammation, inducing angiogene-
sis, and activating invasion and metastasis [238, 239].
A growing body of data describes the accomplishment of
the hallmarks by UM and has recently been reviewed in detail
[240]. Our current knowledge of the steps of UM carcinogen-
esis is summarized in Fig. 2. Almost all UMs are characterized
bymutations in either GNAQ, GNA11, PLCB4, or CYSLTR2
with few cases showing none of these mutations [27, 28, 157,
169]. These mutations are most likely not sufficient for the
establishment of the tumor. The second hit might be an addi-
tional mutation or specific systemic condition such as inflam-
mation or angiogenesis. The progression to invasion and me-
tastasis is driven in most cases by the loss of chromosome 3
and mutation of BAP1. Given the fact that partial deletion of
chromosome 3 only occasionally yields a metastatic pheno-
type, additional factors on chromosome 3 are expected.
Mutations in SF3B1 can also lead to metastasis in the absence
of BAP1 mutations in disomic UM [32].
Amplifications of the long arm of chromosome 8 indepen-
dently contribute to a metastatic phenotype. The V-MycAvian
Myelocytomatosis Viral Oncogene Homolog (MYC) onco-
gene is located on 8q, but its expression does not follow the
amplification status, instead the gene ArfGAP With SH3
Domain, Ankyrin Repeat and PH Domain 1 (ASAP1) also
named DDEF1, AMAP1, or Centaurin-β4, has been proposed
to mediate the effects of 8q amplification [241]. This is par-
ticularly interesting, given the involvement of ARF6 in UM
progression [91] since ASAP1 is a GTPase-activating protein
for ARF1 [242] as well as ARF6 [243].
The molecular basis for the apparent protective effect
of 6p amplifications [244, 245] is unknown. Chromosome
6p contains genes that are involved in the development of
the eye, and congenital deletions lead to eye malformation
main ly invo lv ing the an te r i o r chamber [246] .
Chromosome 6p also harbors the HLA loci and a series
of immunomodulatory genes belonging to the B7-CD28
superfamily [247]. HLA loci are not associated with UM
risk [248] but might play a role in UM progression [249]
through their ability to protect target cells from natural
killer cell-mediated lysis [250].
We have recently reported expression of the B7 family
member Butyrophilin-Like 2 (BTNL2) gene by UM cells
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and macrophages that might contribute to the definition of the
specific immunologic niche [223].
5 Inflammation
In general, chronic inflammation may contribute to early steps
of oncogenesis in different tumor types [251]. Indeed, inflam-
matory cells such as tumor-associated macrophages (TAMs)
and several soluble factors are fundamental components of the
tumor microenvironment and mediate tumor-promoting ef-
fects [252, 253]. The recruitment of monocytes from periph-
eral circulation and their subsequent differentiation to TAMs
is an essential step in establishing the tumor microenviron-
ment, which has several features of a chronic inflammatory
state. Several chemokines, cytokines, and protein products of
the complement cascade contribute to monocyte recruitment
at the tumor site and their differentiation in TAMs [254]. In the
microenvironment, TAMs establish multiple cross-talks with
cancer cells, endothelial cells, fibroblasts and other mesenchy-
mal cells, and lymphoid cells. These interactions result in
tumor progression through the promotion of tumor cell prolif-
eration and survival, angiogenesis, and suppression of anti-
tumor immune responses.
Monocytes andmacrophages have a highly functional plas-
ticity and may undergo divergent functional polarization in
response to activation signals such as cytokines, microbial
components, or products deriving from tissue damage or me-
tabolism [255, 256]. In particular, classical activation with
LPS or IFN-γ induces M1 polarization of macrophages that
results in their ability to produce CXCL9 and CXCL10 anti-
angiogenic chemokines and pro-inflammatory (e.g., TNF-α)
and Th1-polarizing (e.g., IL-12) cytokines. In addition, M1
macrophages acquire cytotoxic properties towards intracellu-
lar pathogens and tumor cells. On the other hand, alternative
activation with IL-4 or IL-13 induces M2 polarization
resulting in the production of CCL17, CCL22, IL-10, pro-
angiogenic factors, and matrix metalloproteinases involved
in tissue remodeling. However, M1- and M2-type macro-
phages represent only the two extremes of a broad spectrum
of functional states which macrophages can acquire in re-
sponse to different stimuli. Within the tumor environment
stimuli such as hypoxia, cytokines produced by cancer cells
(e.g., CCL2, transforming growth factor (TGF)-β, and CSF-1)
or by Treg cells (e.g., IL-10), metabolic products, and immune
complexes may drive TAM functional polarization mainly
towards an M2 status [252].
Several lines of evidence indicate that inflammation and
macrophages play a pro-tumor role also in UM [257]. In UM,
a high density of macrophages was significantly associated
with the presence of epithelioid cells, heavy pigmentation,
and elevated density of microvessels. More importantly, the
presence of high numbers of TAMs in primary tumors corre-
lated with an increased UM-specific mortality rate at 10 years
Fig. 2 Multistep carcinogenesis of UM. The diagram shows a hypothesis
on UM carcinogenesis based on the current state of knowledge of
molecular alterations. UM develops from normal melanoblasts or
melanocytes and is initiated in most cases by mutations in the Gα
proteins, GNAQ or GNA11, or in CYSLTR2 or PLCB4, two genes
acting in the same pathway. An important functional mediator of these
mutations is ARF6 that is activated. The resulting melanoma can undergo
further molecular alterations that influence the risk of progression to
metastasis. Loss of one copy of chromosome 3, mutation of the tumor
suppressor BAP1, and amplification of chr8q yield a high metastatic risk
that can be attenuated by concomitant amplification of chr6p.
Intermediate risk is also observed for cases with chromosome 3 disomy
in the presence of SF3B1mutations.Mutations in EIF1AX and the lack of
any of these mutations are associated with a low risk of metastasis
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[258]. Other studies showed that UM TAMs were predomi-
nantly CD68+CD163+ M2-type macrophages and that their
high density correlated with monosomy 3, ciliary body in-
volvement, increased microvascular density, and worse surviv-
al [259, 260]. Monosomy 3 is a well-known predictive marker
of a poor prognosis in UM, in relationship to the presence on
this chromosome of the tumor suppressor gene BAP1 [148]. It
has been proposed that the loss of BAP1 functionmay favor the
generation of an inflammatory tumor environment [261].
Indeed, in a BAP1(+/−) mouse model, intraperitoneal exposure
to low-dose asbestos fibers showed higher levels of pro-
tumorigenic M2 macrophages and incidence of mesothelioma
than in wild-type littermates [262].
TAMs may also contribute to hepatic metastases, where
CD68+ TAMs showed more intermediate and dendritic cells
associated with a higher microvascular density than the pri-
mary UMs. In addition, the survival of metastatic UM patients
tended to be shorter if hepatic metastases had a high
microvessel density [263]. Altogether, the data from primary
or metastatic UM support the hypothesis that TAMs have pro-
angiogenic and tumor-promoting activities in human UM.
Accordingly, intraocular models of melanoma in syngeneic
mice showed a tumor-promoting role of M2 type macro-
phages, particularly in aged mice [264, 265]. Indeed, deple-
tion of macrophages strikingly inhibited intraocular melano-
ma growth in a syngeneic model [264] and, more recently, in a
transgenic model of UM [266]. Expression of M1/M2 polar-
ization genes is strongly associated with metastatic risk [223].
Regarding the mechanisms stimulating macrophage re-
cruitment, expression of endothelial monocyte-activating
polypeptide (EMAP)-II, detected by immunohistochemistry,
correlated with the accumulation of macrophages in primary
UM. In areas with high EMAP-II, intercellular adhesion mol-
ecule (ICAM)-1 was strongly expressed on endothelial cells.
These results suggested that macrophage recruitment is facil-
itated by the chemotactic activity of EMAP-II and by the
expression of ICAM-1 on vascular endothelial cells [267].
The vitreal concentration of many pro-inflammatory cyto-
kines and chemokines, such as IL-6, CXCL-8, CXCL-10,
CCL-2, CCL-3, CCL-4, CCL-5, and TNF-α, increased in
the eyes of UM patients relative to controls. On the opposite,
the levels of the anti-inflammatory IL-1R antagonist were
lower in UM vitreous. Notably, IL-6 levels positively corre-
lated with high macrophage infiltration [268]. It should be
considered that several of these cytokines may exert
immune-suppressive and M2-polarizing effects. In addition,
co-culture of UM cells with activated T cells upregulated the
expression of chemokines and cytokines such as CXCL8,
CXCL9, CXCL10, CXCL11, CCL2, CCL5, VEGF, and gran-
ulocyte–macrophage colony-stimulating factor (GM-CSF),
which coincided with an enhanced ability to stimulate mono-
cyte chemotaxis [269]. These data suggested that the cross-
talk between tumor cells and T cells may result in the
recruitment of pro-tumoral macrophages. CXCL-8 may be
relevant not only as a pro-inflammatory but also as a pro-
angiogenic factor. In vitro studies suggested that UM may
activate IL-8 signaling as an alternative pro-angiogenic path-
way [270].
Following local treatment of UM by brachytherapy with
ruthenium plaques [271, 272], proton beam irradiation
[273], or trans-pupillary thermotherapy [274], intratumoral
macrophages are always present or even increased in the treat-
ed UM area. These TAMs are frequently engulfed with pig-
ment released by dying tumor cells, thus having the appear-
ance of melanophages. Also, macrophages are present in
extratumoral tissues since brachytherapy may alter their mi-
gration and increase their numbers in the sclera and episclera
[272]. TAMs infiltrating tumors treated by trans-pupillary
thermotherapy predominantly showed a CD68+CD163+ M2
phenotype [274]. However, eyes enucleated after brachyther-
apy showed a lower density of microvessels than those from
untreated UM [263]. In addition, different from untreated UM,
no correlation between the amounts of TAMs and microvas-
cular density was observed in the treated eyes. Altogether,
these data suggest that M2-type macrophages are present in
UM eyes after local treatments, which leads to tumor cell
destruction. Under these circumstances, TAMs may mainly
mediate a clearance of damaged UM cells and tissue repair
but do not exert pro-angiogenic activity.
A small group of patients showed rapid UM regression
associated with inflammation and uveitis following I-125
brachytherapy. Interestingly, these patients had a class 1 tu-
mor, based on gene expression analysis. Class 1 tumors show
higher expression of melanocyte differentiation antigens,
which are recognized by the immune system, relative to class
2 tumors. Therefore, class 1 tumors may be more immuno-
genic than class 2 tumors upon antigen release induced by I-
125 brachytherapy [275].
6 Role of immunity in UM biology and therapy
A growing body of evidence supports an important role of the
immune system in the surveillance of cancers. Indeed, in re-
cent years, immunotherapy by immune checkpoint blockers
has shown unprecedented long-lasting responses in different
metastatic cancers [276]. Cytotoxic T lymphocytes (CTLs),
which recognize tumor-associated antigen (TAA) epitopes in
an HLA class I-restricted manner, play a major role in tumor
cell elimination. Indeed, in different tumors, the presence of an
abundant T cell lymphoid infiltrate rich in CD8+ T cells fre-
quently correlates with a good prognosis [277–279].
However, it became clear that tumors evade from immune
surveillance through several mechanisms. The immune editing
or Bthree e^ theory proposes that the immune system efficient-
ly controls tumor growth in a first phase of tumor cell
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elimination [280]. In a second phase of equilibrium, the im-
mune system still eliminates immunogenic tumor cells but
may also select less immunogenic cell variants. This immune
selection process sculpts the features of clinically evident tu-
mors that are characterized by uncontrolled growth due to
immune escape mechanisms, which are particularly active in
the tumor microenvironment.
Among these mechanisms, the adaptive immune resistance
is due to the induction of programmed death ligand 1 (PDL-1)
expression on tumor cells through IFN-γ released by tumor-
infiltrating CTLs [276]. In turn, PDL-1 switches off the re-
sponse of CD8+ CTLs by engaging the PD-1 inhibitory re-
ceptor at the T cell surface [281]. Antibodies blocking the
PDL-1/PD-1 immune checkpoint restore the silenced immune
response at the tumor site, leading to CTL-mediated tumor cell
lysis. As a matter of fact, anti-PD-1 or anti-PDL-1 blocking
monoclonal antibodies (mAbs) mediate potent and long-
lasting anti-tumor responses in metastatic cutaneous melano-
ma [282, 283] and other metastatic cancers.
The efficacy of immune checkpoint blockers is related to a
high load of tumor non-synonymous mutations, which poten-
tially lead to the generation of immunogenic neo-antigens,
recognized by the T cells [284]. In cutaneous melanoma, the
response to anti-PD-1 therapy has been correlated with the
expression of PL-1 on tumor cells, which is geographically
associated with infiltrating immune cells [285]. More recent
observations related the responsiveness to anti-PD1mAbwith
the abundance of tumor-infiltrating PD-1high/CTLA-4high
CD8+ T cells, which may correspond to exhausted anti-
melanoma-specific CTL [286]. Another clinically relevant im-
mune checkpoint in cutaneous melanoma is CTLA-4, a high-
affinity receptor for the B7.1 and B7.2 co-stimulatory ligands.
Engagement of CTLA-4 with these ligands prevents their in-
teraction with the co-stimulatory receptor CD28 and switches
off Tcell activation [287]. The anti-CTLA-4 mAb ipilimumab
has been the first immune checkpoint blocker approved for
immunotherapy of metastatic melanoma [288].
In spite of their common origin from the neural crests
and the shared expression of differentiation antigens (e.g.,
MART-1, gp100, and tyrosinase), cutaneous melanoma is
highly immunogenic, whereas UM is considered as a
poorly immunogenic tumor [289–291]. The low immuno-
genicity of UM may reflect its peculiar site of origin and
also its biological characteristics.
It is well known that the eye is an immune-privileged organ
and has the ability to prevent the potential damage caused by
the immune response through several mechanisms (reviewed in
[292]). Indeed, skin allografts implanted in the ocular anterior
chamber of rabbits showed prolonged survival, leading to the
concept of the eye immune privilege. Also, the injection of
foreign antigen into the anterior chamber activates suppressor
Tcells, which inhibit the systemic immune response against the
same antigen, a phenomenon defined as anterior chamber-
associated immune deviation (ACAID) [293]. In the mouse,
this phenomenon is related to F480+ macrophages, which de-
velop tolerogenic functions in the eye environment. Upon mi-
gration in lymphoid organs, these macrophages act as antigen-
presenting cells and initiate a response of suppressor T cells
[294]. The aqueous humor contains several immune-
suppressive factors including, for example, the neuropeptides
α-melanocyte-stimulating hormone (MSH) and vasointestinal
polypeptide (VIP), the cytokines macrophage migration-
inhibitory factor (MIF) and TGF-β2. TGF-β inhibits the pro-
inflammatory activity of macrophages and mediates their con-
version to tolerogenic APC-mediating ACAID [295]. In addi-
tion, TGF-β suppresses T cell responses and mediates the con-
version of T cells to immune-suppressive regulatory T cells
[291]. Also, the enzyme indoleamine 2,3-dioxygenase (IDO)
is expressed in the cells lining the anterior chamber cells and
may contribute to inhibiting T and NK cell responses through
tryptophan depletion and generation of kynurenines [296, 297].
It has been proposed that UM cells benefit from the im-
mune privilege in the eye and may adopt several mechanisms
involved in this privilege for tumor escape, also during the
metastatic process [289]. Indeed, UM cells express several
immune-suppressive cytokines found in the eye, including,
for example, TGF-β and MIF, which are inhibitors of NK cell
functions and may therefore contribute to UM metastasis de-
velopment [298]. In addition, UM cells may also express
HLA-E, an MHC class Ib molecule, which binds to the inhib-
itory receptor NKG2A and blocks NK cell functions [299].
Also, classical HLA class I molecules (A, B, and C) protect
target cells from NK-mediated lysis, through the engagement
of inhibitory receptors termed KIRs [300]. Interestingly, the
loss of classical HLA class I molecules is associated with a
better prognosis in UM, opposite to what found in most other
tumors. This finding suggested that NK cells are involved in
immune surveillance of UM, possibly by reducing the chance
of the hematogenous dissemination [250]. Therefore, mecha-
nisms impairing NK cell responses may be relevant in tumor
escape during the metastatic progression of UM. Indeed,
MIC-A/B class I-like molecules, which are ligands of the
NK-activating receptor NKG2D, were found on 50% of pri-
mary UM, but not on metastatic lesions [301].
Notably, opposite to findings reported in other tumors, a
high density of infiltrating lymphocytes in primary UM has
been associated with a worse prognosis [302, 303]. An immu-
nohistochemistry analysis of tumor-infiltrating lymphocytes
(TILs) showed that CD8+ CTLs and, to a lesser extent,
CD4+ T lymphocytes and Treg cells were present in UM
inflammatory infiltrates. In this study, the presence of elevated
numbers of TILs correlated with infiltrating macrophages and
with chromosome 3 monosomy, which is associated with a
worse prognosis [290]. Another study showed that the num-
bers of CD3+ T cells and CD11+ macrophages were correlat-
ed with HLA class I and class II expression, suggesting that
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low levels of HLA expression may lead to a lower inflamma-
tory infiltrate [304]. Overall, these data indicate that the pres-
ence of an inflammatory microenvironment, rich in M2-type
macrophages, T cells, and pro-inflammatory cytokines, may
favor angiogenesis and UM progression [305].
CD4+CD25+FoxP3+ Treg cells are capable of suppressing
Th1/CTL responses and represent a major mechanism of tu-
mor escape in several cancers. Treg cells are present in a
fraction of UM accounting for 12 or 24% of primary UM, in
two different studies [306, 307]. In another study, UM-
infiltrating Treg cells were associated with COX-2 expression
and with worse survival. Indeed, prostaglandin E(2) (PGE(2)
produced by COX-2 is an inducer of Treg cell differentiation
from precursors [307].
Besides M2-type macrophages and Treg cells, it has been
proposed that also PDL-1 expression by UM cells may con-
tribute to immune suppression. UM cell lines treated with
IFN-γ express PDL-1 [308, 309]. In addition, metastatic and
primary UM cell lines upregulating PDL-1 expression upon
IFN-γ stimulation suppressed IL-2 production by Jurkat T
cells in vitro. Either anti-PDL-1 or anti-PD-1 antibodies re-
stored IL-2 production. Although these data indicate that ex-
pression of PDL-1 by UM cells inhibits T function in vitro,
immunohistochemistry showed no PDL-1 expression in pri-
mary UM in vivo [310]. Similarly, IDO is not expressed in
primary or metastatic UM, but it is inducible in UM cell lines
by in vitro stimulation with IFN-γ [311]. These findings sug-
gest that suppressive mechanisms other than PDL-1 and IDO
may dominate in the microenvironment of primary UM.
The weak immunogenic potential of UM may relate to the
lower incidence of somatic mutations than those found in sun-
exposed skin melanomas [312]. Therefore, sun-shielded UMs
may have fewer immunogenic neoepitopes encoded by mu-
tated genes than those found in cutaneous melanoma.
Perhaps the low mutational load may explain the low re-
sponse rates observed in UM patients treated with immune
checkpoint-blocking mAbs. For example, a recent study on
58 patients treated in different academic institutions with anti-
PD-1 (pembrolizumab or nivolumab) or anti-PDL-1 mAb
(atezolizumab) reported a 3.6% overall response rate, 9% of
disease stabilizations, and a progression-free survival of
2.5 months [83]. Also, a phase II study of the anti-CTLA-4
mAb ipilimumab at 3 mg/kg dose has shown limited clinical
activity in pretreated metastatic UM [75]. Another phase II
study of ipilimumab at 10 mg/kg in treatment-naïve metastatic
UM reported better results (10% response rate and overall
survival of 10 months) [261].
A further phase II study of the anti-PD-1 mAb
pembrolizumab is ongoing (NCT02359851), and particular
interest may deserve two clinical studies of the combination
of the anti-PD-1 mAb nivolumab with the anti-CTLA-4 mAb
ipilimumab (NCT01585194 and NCT02626962). This com-
bination has previously shown improved effects, relative to
each mAb alone, in metastatic cutaneous melanoma [313].
Interestingly, also patients with scarce lymphoid infiltrates
and low PDL-1 expression in their tumors, a situation com-
monly found in UM, showed clinical benefit from this com-
bination therapy.
Therefore, although most biological and clinical data sug-
gest that UM is a poorly immunogenic tumor, some piece of
evidence suggests that this may not always be the case. For
example, a pilot study of a gp100 and tyrosinase-based dendrit-
ic cell (DC) vaccination in 14 metastatic UM patients showed a
median overall survival of 19.2 months, longer than that report-
ed in the literature [314]. In addition, recent data support the
existence of an immunogenic UM subset, accounting for 46%
of metastasizing UM, characterized by the absence of melanin
pigmentation in the metastases, as detected by clinical MRI.
These tumors showed the presence of tumor-infiltrating lym-
phocytes capable of mounting an efficient anti-melanoma re-
sponse in vitro, suggesting that this subtype of metastatic UM
may represent an optimal target for immunotherapy [315].
7 Biomarkers
Although less than 1% of UM patients have clinical evidence
of metastasis at the time of diagnosis, about half of them bear a
lifetime risk of fatal progression. Prediction of metastatic risk
in UM patients may be assessed by tumor genotyping to im-
prove the accuracy of clinical and pathological staging [166,
227]. It remains questionable if surveillance strategies for me-
tastases development should differentially apply to patients in
accordance with their risk classification after treatment of the
primary tumor.
Also, it should be considered that primary UM tissue is not
always available for risk assessment and no effective adjuvant
therapies have been established so far. Therefore, the detection
of subclinical micrometastases before they progress may al-
low the early recruitment of patients in clinical trials. Indeed,
local therapy of a limited number of liver lesions was shown to
improve survival [57, 316]. In this respect, the identification
of sensitive blood biomarkers would be particularly useful
both for the early detection of metastases and to monitor the
response to new therapies. Since UM metastatic spread is
preponderant to the liver, liver function tests (LFTs), which
are quite inexpensive and commonly used in the clinic setting,
are mostly used for surveillance. A Finnish study showed a
low sensitivity but high specificity of individual LFTs, with
lactate dehydrogenase (LDH) being the most sensitive param-
eter. Notably, the authors showed that the association of LFTs
with abdominal ultrasonography (USG) every 6 months
would identify over 95% of asymptomatic patients [317].
However, a more recent study showed that the sensitivity
and metastasis prediction value of LFTs is very poor, although
normal LFTs have a negative predictive value of 90% and
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identify patients with low chance of having metastases [318].
Also, a retrospective study on a cohort of 263 UM patients
showed that only 13% of patients with USG-detectable me-
tastasis had simultaneous abnormal LFTs [319].
In the search for better serum biomarkers, S100-β, a reliable
biomarker for monitoring CM, was tested in UM patients but
showed limited utility. Indeed, S100-β serum levels showed no
correlations with other prognostic parameters or development of
metastases [320]. Another protein biomarker considered has
been melanoma inhibitory activity (MIA). However, serum
levels of MIA increased only after clinical detection of metasta-
ses [321, 322]. In another study, the combination of S100-β and
LDH performed better in identifying UM metastases than γ-
glutamyl transpeptidase and MIA alone [323]. Elevated serum
levels of MIA, S100-β, and osteopontin (OPN) correlated with
liver UM metastases, and the combination of these three bio-
markers enhanced the sensitivity and specificity in detecting he-
patic metastases [324]. Serum levels of cytokeratin 18 (TPS)
[325], insulin-like growth factor 1 (IGF1) [326], growth differ-
entiation factor 15 (GDF15) [327], and Parkinson protein N7
(PARK7 or DJ-1) [328] are significantly more elevated in meta-
static than in metastasis-free patients. An increase in VEGF on
serial measurements might indicate the presence of metastases,
but its value was limited by the large variability among patients
[329]. We recently showed that patients with metastatic UM
display significantly higher serum levels of a soluble form of
the hepatocyte growth factor receptor c-Met (sc-Met) than
metastasis-free patients and healthy donors. Analyses of receiver
operating characteristic (ROC) curves showed that sc-Met per-
forms better than S100-β and LDH in the identification of UM
liver metastases. Serial measurement in patients with metastatic
disease showed a progressive rise of sc-Met levels whereas in
disease-free patients, sc-Met levels were stable [330]. None of
these biomarkers have entered into clinical practice so far.
Indeed, prospective studies with a large cohort of patients are still
necessary to identify biomarkers or a combination of themwith a
predictive value of the early development of metastases.
7.1 Circulating tumor cells, DNA, miRNA, and exosomes
Circulating tumor cells (CTCs) in the blood have been pro-
posed as a prognostic biomarker, potentially useful to monitor
the response to therapy in patients with metastatic carcinoma
[331]. Since UMmetastasizes through hematogenous dissem-
ination, it is conceivable that detection of circulating UM cells
into the blood may be useful for monitoring disease progres-
sion or response to treatment.
Different technical approaches have been used to detect or
isolate UM CTCs, including immunomagnetic sorting [332],
enrichment by size of tumor cells [333], or RT-PCR detection
of tyrosinase and MelanA/MART1 mRNA [334]. Variable
results have been reported on the prognostic value of CTC
detection in UM, and comparisons among studies are difficult
due to the different methodologies applied.
CTCs expressing the melanoma-associated chondroitin sul-
fate proteoglycan (MCSP) were isolated by immunomagnetic
cell sorting in 10 of 52 patients with primary UM. The presence
of CTCs showed correlation with clinical parameters of pro-
gression but not with the outcome due to the short follow-up
[335]. However, a subsequent study involving 81 primary UM
patients did not confirm these results. Indeed, the presence and
number of CTCs isolated by the same technique showed no
significant association with prognostic parameters or with met-
astatic progression and no therapy-related changes [336]. A
recent s tudy repor ted the isola t ion of CTCs by
immunomagnetic sorting of CD146 (MUC18)-positive cells,
which were further characterized for high molecular weight
melanoma-associated antigen (MEL) expression in four of
eight patients with primary, not metastatic UM whereas no
CTCs were found in four choroidal nevus patient [337]. The
small patient sample did not allow a correlation of CTC number
and prognosis. Also, the combination of two monoclonal anti-
bodies against a melanoma-associated glycoprotein was used
for CTC immunomagnetic sorting from the blood of 31 UM
patients without metastatic disease. The presence or number of
CTCs did not show a significant association with clinical prog-
nostic factors [332]. One recent study combined the isolation of
CTCs with the same technology with immuno-FISH detection
of monosomy of chromosome 3 in 44 primary UM patients.
Monosomy 3 was detected in intact CTCs of 58% of patients
and was confirmed in the primary tumor of 10 out of 11 tested
patients [338]. These results suggest that the FISH–cytogenet-
ics of CTCs might provide useful prognostic information, par-
ticularly in UM patients not undergoing surgery or biopsy.
A different approach for identifying CTCs is based on RT-
PCR analysis of melanoma-associated transcripts. The pres-
ence of CTCs detected by RT-PCR of tyrosinase or MelanA/
MART1 transcripts represented an independent prognostic fac-
tor for metastases and survival, in patients with high-risk pri-
mary UM [339]. Also, in metastatic UM patients, the RT-PCR
detection of CTCs resulted to be a poor prognostic factor [340].
Therefore, the prognostic value of the presence or number
of CTCs in the blood of UM patients differs depending on the
methods of detection and further studies are needed to better
define the significance of CTCs as a biomarker in UM.
Circulating tumor DNA (ctDNA) has also been detected in
different tumors and correlated with disease burden, progno-
sis, and response to therapy [341]. Most of the circulating free
DNA (cfDNA) present in healthy individuals derives from
physiologic apoptosis of hematopoietic cells. The contribution
of tumor cells on the blood DNA is limited and depends on
tumor burden or cell turnover [342]. Therefore, quantification
of ctDNA needs to be associated with detection of a tumor-
specific mutation that identifies cfDNA of tumor origin. The
development of powerful sequencing techniques has
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improved the limit of detection of ctDNA copies in the total
normal DNA from 10% by Sanger sequencing up to 1–2% by
ultradeep sequencing [343] and 0.01% by droplet digital PCR
(ddPCR) [344]. The comparative analysis of CTC detection
and that of the quantification of ctDNA bearing UM-specific
GNAQ/GNA11 mutations showed that both CTC and ctDNA
levels were associated with the presence of miliary hepatic
metastasis and with poor disease-free and overall survival.
However, in multivariate analyses, ctDNAwas a better prog-
nost ic marker than CTCs [345] . A cl inical t r ia l
(NCT02849145) is recruiting participants to evaluate the
ctDNA in the blood, before and after resection of hepatic
metastasis of UM and during post-surgery follow-up.
Serum microRNA (miRNA) are also attractive biomarkers
of tumor progression and response to therapy and are mostly
encapsulated within vesicles of endosomal origin from 30 to
150 nm known as exosomes [346, 347] MicroRNA are small
non-coding RNA involved in different biological processes
through the regulation of gene expression at the post-
transcriptional level. Two studies [348, 349] reported higher
levels of miR146a in the serum of patients with primary UM
than those of healthy controls, and levels were even higher in
patients undergoing metastatic progression. MicroR146a is
involved in NK cell function and inflammation and is upreg-
ulated by the MAPK cascade, which is activated by GNAQ/
GNA11 mutations in UM. A study investigated the presence
of exosomes and their miRNA content in the liver perfusate of
12 patients with UM liver metastases. MelanA-positive
exosomes were present in the liver circulation in metastatic
UM, with similar miRNA profiles among patients. Also, the
peripheral blood contained higher levels of exosomes com-
pared to healthy controls [350]. Further studies with the larger
number of patients are required to evaluate the role of circu-
lating miRNA and exosomes as biomarkers for the early de-
tection of distant metastases.
8 Animal models
A spontaneous UMmight be the ideal animal model, provided
that it would reproduce the human disease. Although rare
cases of spontaneous intraocular melanomas have been report-
ed in different animal species, including dogs [351, 352], cats
[353, 354], horses [355], and cattle [356], no spontaneous
UMs were reported in mice, which would represent the most
convenient species. Syngeneic transplantable and transgenic
models of UM allow investigating the interaction between the
host immune system and the tumor. On the other hand, in vivo
xenotransplantation models of human UM require immune-
deficient hosts. The subcutaneous implant of patient-derived
UM fragments (patient-derived xenografts, PDXs) is of spe-
cial interest since PDXs reproduce the genetic, histopatholog-
ical, and biological properties of the original human tumor.
Considering the implant of UM cell suspensions, the injec-
tion site is of crucial importance. UM cells may be
orthotopically injected in the posterior or anterior chamber of
the eye to better mimic primary tumor growth. Different routes
of injection may be used to mimic metastatic dissemination,
such as injection into the spleen, liver, tail vein, or heart. In
addition, the genetic features of human UM cell lines, such as
GNAQ or GNA11 mutations, chromosome 3 monosomy,
BAP1 mutation, and liver tropism, should be considered.
Hence, the development of UM in vivo models of spon-
taneous liver metastases should be an important issue and
may be helpful in the preclinical testing of new therapeu-
tic strategies.
8.1 Syngeneic models
Most syngeneic models were based on the mouse cutaneous
melanoma cell line B16 or its metastatic variant B16F10 [357,
358], mostly injected into the eye of C57BL6 mice. In addi-
tion, the subline B16LS9 has been derived by repeated in vivo
passages to select for melanoma cells with metastatic tropism
to the liver, to better reproduce the human metastatic disease.
Intraocular injection of B16LS9 cells has been utilized as an
orthotopic syngeneic model producing liver metastases [359].
The syngeneic orthotopic models have been used to study
immunologic aspects of UM development such as the inhibi-
tory effect of NK T cell-derived IL-10 on the anti-metastatic
activity of NK cells [360]. A recent study showed that activa-
tion of NK cells by administration of the Toll-like receptor-5
agonist entolimod suppressed the development of spontane-
ous hepatic metastases in the orthotopic B16LS9 model [361].
The growth of primary ocular tumor derived by the orthotopic
implant of B16LS9 cells with the p53 activator Nutlin-3 and
the topoisomerase inhibitor topotecan delayed tumor growth
[362]. Although relevant information on UM derives from
syngeneic models, it should be taken into account that the
results obtained using B16 melanoma cells or their derivatives
may not reflect the biology of the human UM. B16 cells carry
a BRAF mutation that is very rare in UM.
8.2 Xenotransplantation models
Historically, the first xenotransplantation animal models mim-
icking UM were developed by implantation of hamster mela-
noma tissue in the anterior chamber of rabbits (Greene HS
PMID: 5934903). Human xenograft models of UM have been
established in immune-deficient mice [363] and rats [364],
rabbits [365], and zebrafish [366]. Established primary uveal
melanoma cell lines have been injected into the anterior or
posterior chamber and into the ciliary body or choroid. For
example, OCM1, OCM3, OCM8, EOM3, 92.1, OM431, and
MEL202 were injected intracamerally into nu/nu BALB/c
(H-2d) mice [367]. In this study, OCM1 and 92.1 cells gave
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rise to liver metastasis at day 50 with an incidence of 80%.
However, the OCM1 cell line harbors the BRAF V600E mu-
tation typical of CM, while it is wild type for GNAQ, GNA11,
and BAP1. Differently, 92.1 cell bears the GNAQ Q209L
driver mutation, but is wild type for the BAP1 gene. In addi-
tion, both cell lines are disomic for chromosome 3 and there-
fore lack the main features of UM at high metastatic risk.
Patients with ciliary body or choroid melanomas have me-
tastasis with higher frequency and have a worse prognosis. To
mimic this situation, MEL290 UM cells, transduced by
lentiviral EGFP encoding for a fluorescent protein, were
injected into the posterior chamber of the eye of nu/nu mice.
This approach led to micrometastasis development into the
liver at 4–6 weeks after transplantation with an incidence of
100% [368]. Moreover, more liver micrometastases devel-
oped in the intraocular model than in the tail injection model.
Orthotopic xenograft models have been used for the
preclinical assessment of new treatments [369–371]. For
example, the UM cell line OMM1.3, bearing a GNAQ
Q209P mutation, retro-orbitally injected into nu/nu mice
developed liver metastases 9 weeks post injection. In this
model, treatment with the c-Met/ALK tyrosine kinase in-
hibitor crizotinib prevented liver metastasis development
without blocking ocular tumor growth [98]. These data
point out to an important role of the HGF/c-Met axis in
metastatic spreading of UM to the liver.
The majority of human metastatic UM has chromosome 3
loss and BAP1 mutation; however, xenograft models using
monosomic human UM cells have not been developed so
far. Surprisingly, OCM1A, 92.1, and Mel290 cell lines, si-
lenced for the expression of BAP1, gave rise to smaller tumors
or developed fewer metastases than BAP1 WT cells when
injected subcutaneously or intravenously, respectively [209].
Pseudo-metastatic xenotransplantation models of UM have
also been obtained by intracardiac or tail vein injection [368,
372] or by implant into the liver [325, 373] or spleen [89, 374,
375]. Spleen transplantation allows UM cells to reach and col-
onize the liver through the portal circulation. It has been used as
a pseudo-metastatic model to evaluate treatment, mechanisms
of metastasis, or UM biomarkers [89, 330, 376–378]. For ex-
ample, preliminary detection of human-soluble sc-Met in the
serum of UMxenograft led to the identification of this molecule
as a potential biomarker of metastases in UM patients [330].
The human GNAQ-mutated UM cell line TJU-UM001,
transplanted under the spleen capsule of NSG mice, developed
multiple hepatic metastases whereas lung metastases were not
observed. Interestingly, a laminin-rich vasculogenic mimicry
pattern was seen in the hepatic lesions similar to that observed
in primary and metastatic human UMs [379].
PDXs were generated from primary or metastatic UM
tissues to propagate tumors in vivo, for pathogenesis and
preclinical therapy studies. Transplantation of UM frag-
ments into the subcutis or the interscapular fat pad of
nu/nu [380] or SCID [381] mice yielded a low take rate.
Tumor takes were significantly higher when implanted
fragments were derived from metastases as compared to
those derived from primary tumors (52.9%). Interestingly,
engraftment of metastatic tumors was predictive of a short
overall survival of metastatic patients. In addition, xeno-
graft growth of primary tumors inversely correlated with
5-year metastasis-free survival [381]. The comparison of
serial UM xenografts to the original tumor showed that
xenografts are genetically stable over in vivo passages and
maintain the genetics features of the original human UM
[382]. Despite the limits of a low rate of engraftment and
growth delay after initial transplantation, panels of UM
PDXs have been employed to test combinations of
targeted therapies [383, 384].
Human UM cell line xenografts have also been developed
in rabbits which bear larger eyes than mice and are therefore
more suitable for examination and surgical procedures, upon
immunosuppression with cyclosporine-A. However, in these
models, most of the metastases were found in the lungs and
rarely in the liver [385–387].
Injection of human UM cell lines into the chick embryo,
which lacks an immune system till days 10–15, has also been
used as an easily accessible and economical xenograft model
[388, 222]. Preliminary data of the chick embryo metastasis
model show that OMM1 and 92.1 cells injected into the cir-
culation of 7-day embryos mostly colonize tissues of neural
crest derivation [389].
Recently, human UM xenotransplantation models were
established in zebrafish using cell lines derived from primary
UM or metastatic UM expressing a red fluorescent protein.
This model was suitable to test the efficacy of different exper-
imental anticancer drugs (e.g., quisinostat and the neddylation
[ubiquitin-like protein NEDD8 conjugation to target proteins]
pathway inhibitor MLN-4924) which repressed the migration
and proliferation of UM cells. As the drugs were dissolved in
the water, the rate of drug absorbance into zebrafish embryos
needs a better characterization [390].
8.3 Transgenic mouse models
Transgenic animals, which constitutively express an onco-
gene, represent a useful tool for the study of tumorigene-
sis in vivo and to explore tumor–host interactions in the
tumor microenvironment [391]. Several transgenic mouse
models of CM, which resemble the biological features of
the human disease, also develop a choroidal melanoma,
although they do not bear mutations typical of human UM
[265]. Very recent studies exploited the activated GNAQ
oncogene, which is found in a significant fraction of hu-
man UM, to develop transgenic UM models.
One of the earliest CM models has been the MT-ret trans-
genic mice, which express the human RET oncogene
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controlled by the mouse metallothionein I promoter–enhancer.
These mice develop hyperplastic and tumoral lesions in dif-
ferent melanocyte-containing tissues [392]. Although Ret ki-
nase mutations have not been found in human melanomas, the
RET oncogene stimulates the downstream MAP kinase path-
ways, which are typical of melanoma [393] and may explain
melanoma formation, in the transgenic mice. These mice also
develop UM as an early event, revealed by exophthalmos
[392]. MT-ret transgenic mice were also crossed with ADD
transgenic mice, which express the chimeric MHC molecule
AAD (HLA-A2/H2-Dd). These MT-ret/AAD mice are suit-
able for analyzing CD8+ T cell responses directed against
immunogenic antigens found in HLA-A2+melanoma patients
[394]. This model allowed establishing the pro-metastatic ef-
fects of macrophages, which could be abrogated by treatment
with the CSF-1R-specific kinase inhibitor Ki20227 [266]. In
another study, the effect of the pro-inflammatory and autoim-
mune background of the non-obese diabetic (NOD) strain was
assessed by back-crossing MT-ret with NOD mice, which
resulted in rapid UM development. Dectin-1 expression was
reduced in granulocytic myeloid cells in relationship with an
increase of regulatory T cells and that of IFN-γ-producing
CD8+ Tcells in tumors. IFN-γ-inducible nitric oxide synthase
(Nos2) was involved in inflammation and accelerated tumor-
igenesis. These data point to a role of inflammation in UM
development and to dectin-1 and Nos2 as potential therapeutic
targets [395].
Mice bearing targeted deletions of oncosuppressor genes
can be generated to mimic a cancer-prone condition. These
mice can be eventually crossed with transgenic mice bearing
active oncogenes to enhance the oncogenic effect of the trans-
gene. This is the case of spontaneous malignant melanomas
occurring inmale Tyr-RAS+ Ink4a/Arf−/− transgenic mice. In
these mice, a human tyrosinase enhancer/promoter element
drives melanocyte-specific expression of a human activated
H-ras gene integrated into the Y chromosome. Such transgen-
ic mice crossed in an Ink4a/Arf-deficient background (Tyr-
RAS+ Ink4a/Arf−/−) develop CM and UM, in males [396].
These UMs showed epithelioid- and spindle-shaped features
and local invasiveness resembling the human counterpart but
no metastatic progression [397].
In Tg(Grm1)EPv transgenic mice, the metabotropic gluta-
mate receptor 1 (Grm1) gene is under the control of the
dopachrome tautomerase (Dct, Trp2) promoter, specifically
expressed in melanocytes [398]. These mice develop melano-
mas, in the hairless skin of ear, tail, and anus, and also develop
choroidal hyperplastic lesions and UM-like tumors.
Furthermore, GRM1 is expressed in human uveal and skin
melanoma, suggesting that the glutamate signaling pathway
is a possible target for UM therapy [399].
Recently, the first transgenic mouse model, reproducing ge-
netic defects of human UM, has been developed. A transgenic
mouse strain, expressing oncogenic GNAQ(Q209L) under
control of the Rosa26 promoter, showed not only UM but also
dermal nevi and other melanocytic tumors of the central ner-
vous system [400]. In this model, the Yap protein was activated
in the eyes, and uveal blood vessels showed melanocytic inva-
sion. However, most of these mice developed metastases only
in the lungs. This model is the first transgenic mouse model
using a relevant oncogene of human UM and may represent a
tool for testing new targeted therapies in vivo.
A transgenic model of spontaneous UM was also
established in zebrafish, engineered to express oncogenic
GNAQ(Q209P) in the melanocyte lineage. These zebrafishes
display hyperplasia of uveal melanocytes, but no evidence of
tumor progression. However, the combined expression of
GNAQ(Q209P) with p53 oncosuppressor inactivation medi-
ated an earlier onset of hyperplastic lesions that evolved in
UM. A weak phosphorylation of ERK1/2 was observed in
transgenic UM, while staining for nuclear YAP was evident.
Therefore, enhanced ERK1/2 signaling seems not a major
feature of GNAQ(Q209P)-driven transgenic UM [401].
Recently, cells from a genetically modified mouse strain
were used to identify new potential targets for UM. Ric-8A
is a molecular chaperone that folds GNAQ and GNA11 sub-
units and may therefore serve as a target to reduce the abun-
dance of these oncoproteins in UM. Melanocytes obtained
from a conditional Ric-8AFlox/Flox; Rosa-CreER+/− mouse
strain transduced with the human GNAQQ209L showed au-
tonomous cell proliferation in vitro and, upon grafting in mice,
developed melanoma tumors. Deletion of Ric-8A in GNAQ
Q209L-transduced cells by tamoxifen reduced Gαq-Q209L
levels and prevented tumorigenesis in vivo. Also, phorbol es-
ter (TPA) treatment inhibited GNAQ Q209L cell proliferation
in vitro and in vivo. The authors propose Ric-8A inhibition or
phorbol esters as novel potential treatments of UM [402].
9 Conclusions
The last years have brought a dramatic progress of our under-
standing of UM. The evolution of this rare cancer is now
described in considerable detail in terms of cytogenetic, ge-
netic, and transcriptional alterations as well as the signaling
pathways involved in the formation of UM and its progression
to metastasis. We still have a limited understanding of several
central aspects of the disease:
– The etiology of UM
– The ontogenetic cellular origin of UM and its precursor
cells
– The role in metastasis of chromosome 3 monosomy as
opposed to losses of single regions of the same
chromosome
– The molecular basis of the effects of minor cytogenetic
alterations (6p, 1p)
126 Cancer Metastasis Rev (2017) 36:109–140
– The precise way of action of BAP1
– Metastatic players in BAP1/SF3B1 wild-type metastatic
UM
– The role of epigenetic alterations
– The determinants of the liver tropism of UM metastases.
Most importantly, our understanding has so far not led to a
sensible improvement in survival of patients with metastatic
UM. Research should therefore be focused on the translation
of the mechanistic understanding of the disease into proposals
for clinical trials using drugs that are targeted at UM-specific
molecular alterations. This should hopefully lead to an in-
crease in survival of metastatic patients similar to what has
recently been observed for CM patients.
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